The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23 inhibitor ustekinumab (Janssen’s Stelara) is increasingly being challenged by novel, highly effective IL-17 and IL-23 inhibitors. In particular, the uptake of risankizumab (AbbVie’s Skyrizi)—the latest IL-23 inhibitor to be approved for psoriasis—has been phenomenal, raising concerns among developers of other approved biologics regarding the future uptake of their agents. The launches of deucravacitinib, an oral tyrosine kinase (TYK)2 inhibitor, and the nonsteroidal topical agents roflumilast and tapinarof have further increased the number of psoriasis treatments. Also, the anticipated approval of bimekizumab in the United States, following its approvals in Europe and Japan, will make the market even more competitive.
Questions answered:
Content highlights:
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 36 country-specific interviews with thought leaders. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Total diagnosed prevalence of psoriasis by country, segmented by mild and moderate to severe subpopulations.
Emerging therapies: Phase III/PR: 2 drugs; Phase II: 10 drugs; coverage of select preclinical and Phase I products.
Forecast: 10-year, annualized, drug-level sales and patient share of key psoriasis therapies through 2031, segmented by brands/generics and epidemiological subpopulations.
Product description:
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement:
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.